Evidence map›Paper›PMID 27347765›Full record

ArticleRadiology2016

Hepatocellular Carcinoma: Intra-arterial Delivery of Doxorubicin-loaded Hollow Gold Nanospheres for Photothermal Ablation-Chemoembolization Therapy in Rats.

Junjie Li, Min Zhou, Fengyong Liu, Chiyi Xiong, Wanqin Wang, Qizhen Cao, Xiaoxia Wen, J David Robertson, Xin Ji, Y Andrew Wang and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Radiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Theranostics · 2018
    Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Junjie LiFrom the Departments of Cancer Systems Imaging (J.L., M.Z., C.X., W.W., Q.C., X.W., C.L.) and Interventional Radiology (F.L., S.G.), the University of Texas MD Anderson Cancer Center, Houston, 1515 Holcombe Blvd, TX 77030; Department of Chemistry, University of Missouri, Columbia, Mo (J.D.R.); and Ocean Nanotech, San Diego, Calif (X.J., Y.A.W.).
Min ZhouFrom the Departments of Cancer Systems Imaging (J.L., M.Z., C.X., W.W., Q.C., X.W., C.L.) and Interventional Radiology (F.L., S.G.), the University of Texas MD Anderson Cancer Center, Houston, 1515 Holcombe Blvd, TX 77030; Department of Chemistry, University of Missouri, Columbia, Mo (J.D.R.); and Ocean Nanotech, San Diego, Calif (X.J., Y.A.W.).
Fengyong LiuFrom the Departments of Cancer Systems Imaging (J.L., M.Z., C.X., W.W., Q.C., X.W., C.L.) and Interventional Radiology (F.L., S.G.), the University of Texas MD Anderson Cancer Center, Houston, 1515 Holcombe Blvd, TX 77030; Department of Chemistry, University of Missouri, Columbia, Mo (J.D.R.); and Ocean Nanotech, San Diego, Calif (X.J., Y.A.W.).
Chiyi XiongFrom the Departments of Cancer Systems Imaging (J.L., M.Z., C.X., W.W., Q.C., X.W., C.L.) and Interventional Radiology (F.L., S.G.), the University of Texas MD Anderson Cancer Center, Houston, 1515 Holcombe Blvd, TX 77030; Department of Chemistry, University of Missouri, Columbia, Mo (J.D.R.); and Ocean Nanotech, San Diego, Calif (X.J., Y.A.W.).
Wanqin WangFrom the Departments of Cancer Systems Imaging (J.L., M.Z., C.X., W.W., Q.C., X.W., C.L.) and Interventional Radiology (F.L., S.G.), the University of Texas MD Anderson Cancer Center, Houston, 1515 Holcombe Blvd, TX 77030; Department of Chemistry, University of Missouri, Columbia, Mo (J.D.R.); and Ocean Nanotech, San Diego, Calif (X.J., Y.A.W.).
Qizhen CaoFrom the Departments of Cancer Systems Imaging (J.L., M.Z., C.X., W.W., Q.C., X.W., C.L.) and Interventional Radiology (F.L., S.G.), the University of Texas MD Anderson Cancer Center, Houston, 1515 Holcombe Blvd, TX 77030; Department of Chemistry, University of Missouri, Columbia, Mo (J.D.R.); and Ocean Nanotech, San Diego, Calif (X.J., Y.A.W.).
Xiaoxia WenFrom the Departments of Cancer Systems Imaging (J.L., M.Z., C.X., W.W., Q.C., X.W., C.L.) and Interventional Radiology (F.L., S.G.), the University of Texas MD Anderson Cancer Center, Houston, 1515 Holcombe Blvd, TX 77030; Department of Chemistry, University of Missouri, Columbia, Mo (J.D.R.); and Ocean Nanotech, San Diego, Calif (X.J., Y.A.W.).
J David RobertsonFrom the Departments of Cancer Systems Imaging (J.L., M.Z., C.X., W.W., Q.C., X.W., C.L.) and Interventional Radiology (F.L., S.G.), the University of Texas MD Anderson Cancer Center, Houston, 1515 Holcombe Blvd, TX 77030; Department of Chemistry, University of Missouri, Columbia, Mo (J.D.R.); and Ocean Nanotech, San Diego, Calif (X.J., Y.A.W.).
Xin JiFrom the Departments of Cancer Systems Imaging (J.L., M.Z., C.X., W.W., Q.C., X.W., C.L.) and Interventional Radiology (F.L., S.G.), the University of Texas MD Anderson Cancer Center, Houston, 1515 Holcombe Blvd, TX 77030; Department of Chemistry, University of Missouri, Columbia, Mo (J.D.R.); and Ocean Nanotech, San Diego, Calif (X.J., Y.A.W.).
Y Andrew WangFrom the Departments of Cancer Systems Imaging (J.L., M.Z., C.X., W.W., Q.C., X.W., C.L.) and Interventional Radiology (F.L., S.G.), the University of Texas MD Anderson Cancer Center, Houston, 1515 Holcombe Blvd, TX 77030; Department of Chemistry, University of Missouri, Columbia, Mo (J.D.R.); and Ocean Nanotech, San Diego, Calif (X.J., Y.A.W.).
Sanjay GuptaFrom the Departments of Cancer Systems Imaging (J.L., M.Z., C.X., W.W., Q.C., X.W., C.L.) and Interventional Radiology (F.L., S.G.), the University of Texas MD Anderson Cancer Center, Houston, 1515 Holcombe Blvd, TX 77030; Department of Chemistry, University of Missouri, Columbia, Mo (J.D.R.); and Ocean Nanotech, San Diego, Calif (X.J., Y.A.W.).
Chun LiFrom the Departments of Cancer Systems Imaging (J.L., M.Z., C.X., W.W., Q.C., X.W., C.L.) and Interventional Radiology (F.L., S.G.), the University of Texas MD Anderson Cancer Center, Houston, 1515 Holcombe Blvd, TX 77030; Department of Chemistry, University of Missouri, Columbia, Mo (J.D.R.); and Ocean Nanotech, San Diego, Calif (X.J., Y.A.W.).
The University of Texas MD Anderson Cancer Center · USOcean NanoTech (United States) · USUniversity of Missouri · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Multifunctional Hollow Gold Nanospheres for Concurrent Photothermal-ChemotherapyR44CA196025 · NCI · OCEAN NANOTECH, LLC · PI LI, CHUN, WANG, YONGQIANG ANDREW · 2015 to 2016
$1.0M
NCI NIH HHS P30 CA016672NCI NIH HHS R44 CA196025
6 · The paper itself

Abstract

Purpose To determine if combretastatin A-4 phosphate disodium (CA4P) can enhance the tumor uptake of doxorubicin (Dox)-loaded, polyethylene glycol (PEG)-coated hollow gold nanospheres (HAuNS) mixed with ethiodized oil for improved photothermal ablation (PTA)-chemoembolization therapy (CET) of hepatocellular carcinoma (HCC) in rats. Materials and Methods Animal experiments were approved by the institutional animal care and use committee and performed from February 2014 to April 2015. Male Sprague-Dawley rats (n = 45; age, 12 weeks) were inoculated with N1S1 HCC cells in the liver, and 8 days later, were randomly divided into two groups of 10 rats. Group 1 rats received intrahepatic arterial injection of PEG-HAuNS and ethiodized oil alone; group 2 received pretreatment with CA4P and injection of PEG-HAuNS and ethiodized oil 5 minutes later. The gold content of tumor and liver tissue at 1 hour or 24 hours after injection was quantified by using neutron activation analysis (n = 5 per time point). Five rats received pretreatment CA4P, PEG-copper 64-HAuNS, and ethiodized oil and underwent micro-positron emission tomography (PET)/computed tomography (CT). In a separate study, three groups of six rats with HCC were injected with saline solution (control group); CA4P, Dox-loaded PEG-coated HAuNS (Dox@PEG-HAuNS), and ethiodized oil (CET group); or CA4P, Dox@PEG-HAuNS, ethiodized oil, and near-infrared irradiation (PTA-CET group). Temperature was recorded during laser irradiation. Findings were verified at postmortem histopathologic and/or autoradiographic examination. Wilcoxon rank-sum test and Pearson correlation analyses were performed. Results PEG-HAuNS uptake in CA4P-pretreated HCC tumors was significantly higher than that in non-CA4P-pretreated tumors at both 1 hour (P < .03) and 24 hours (P < .01). Mean ± standard deviation of tumor-to-liver PEG-HAuNS uptake ratios at 1 hour and 24 hours, respectively, were 5.63 ± 3.09 and 1.68 ± 0.77 in the CA4P-treated group and 1.29 ± 2.40 and 0.14 ± 0.11 in the non-CA4P-treated group. Micro-PET/CT allowed clear delineation of tumors, enabling quantitative imaging analysis. Laser irradiation increased temperature to 60°C and 43°C in the tumor and adjacent liver, respectively. Mean HCC tumor volumes 10 days after therapy were 1.68 cm

Indexed as

AnimalsCarcinoma, HepatocellularCell Line, TumorChemoembolization, TherapeuticDisease Models, AnimalDoxorubicinDrug CarriersEthiodized OilGoldHyperthermia, InducedLiver NeoplasmsMaleNanospheresPolyethylene GlycolsPositron Emission Tomography Computed TomographyRandom AllocationDoxorubicinDrug CarriersEthiodized OilfosbretabulinGoldPolyethylene GlycolsStilbenes

Identifiers

PMID27347765
PMCPMC5069072
OpenAlexW2471505960

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.